









## Humber Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on 7<sup>th</sup> December 2022

### Classification of products:

Status	Description
 <b>GREEN</b>	Medicines suitable for routine use within primary care and Secondary care. May be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies
 <b>AMB 1</b>	Specialist recommendation: These medicines are considered suitable for GP prescribing following specialist recommendation or via an APC approved prescribing guideline.
 <b>AMB 2</b>	Specialist initiation: These medicines are considered suitable for GP prescribing following specialist initiation, including titration of dose and assessment of efficacy. These medicines may also have an APC approved guideline to aid GPs in further prescribing.
 <b>AMB SCP</b>	AMBER SHARE CARE PROTOCOL- Specialist initiation with ongoing monitoring: Medicines that must be initiated by a specialist, and which require significant monitoring on an ongoing basis. Full agreement to share the care of each specific patient must be reached under the shared care protocol which must be provided to the GP. If a commissioned shared care is not available in CCG/place then these drugs must be treated as red drug (hospital only).
 <b>RED</b>	Red-Hospital initiation and continuation only
 <b>GREY</b>	GREY- NON FORMULARY (As agreed by Area Prescribing Committee)
 <b>PURPLE</b>	To be supplied from the appropriate commissioned provider.
 <b>NR</b>	Not routinely commissioned

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
<b>1) Requests deferred from previous meetings</b>				
Nil this month				
<b>2) New Requests</b>				
Pirobutinib	<b>RED</b>			HUTH only free of charge scheme in NHSE service
Icosapent ethyl	<b>AMB 1</b>			Updated lipid pathway approved
Tecovirimat	<b>RED</b>			Approved in line with NHSE guidance
Itulazax® Birch pollen extract	<b>RED</b>			
Pentazocine	<b>RED</b>			For cough clinic in HUTH only

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
<b>3) New formulations &amp; extensions to use</b>				
Oraltek ®(dog dander extract)	RED			Due to availability issue with OralVac®
<b>4) Products considered by NICE</b>				
TA827: Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA828: Ozanimod for treating moderately to severely active ulcerative colitis	RED			The formulary will reflect the TAG – ICB is the responsible commissioner.
TA830: Pembrolizumab for adjuvant treatment of renal cell carcinoma	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA831: Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA832: Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids	AMB 2			The formulary will reflect the TAG – ICB is the responsible commissioner. When pathway received from services classification can be revisited.
TA835: Fostamatinib for treating refractory chronic immune thrombocytopenia	RED			The formulary will reflect the TAG – ICB is the responsible commissioner.
TA836: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA837: Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
<b>5) Appeals against earlier decisions by the APC</b>				
Nil this month				
<b>6) Miscellaneous formulary decisions by the APC</b>				
Nil this month				

The following guidelines were presented to and approved at the December 2022 meeting of the APC:

- Gastrointestinal tract infections (Hull and East Riding Yorkshire ONLY)
- Secondary CVD prevention pathway

The following drug information leaflets were presented to and approved at the December 2022 meeting of the APC:

- Nil this month

The following shared care guidelines were presented to and approved at the December 2022 meeting of the APC:

- Grazax SCF Hull and ERY
- Lithium for Cluster headache

Other documents presented to and approved at the December 2022 meeting of the APC:

- APC newsletter